Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline

Projektinformationen

RespiriNTM

ID Finanzhilfevereinbarung: 853932

DOI

10.3030/853932

EK-Unterschriftsdatum 8 Mai 2019

Startdatum 1 Mai 2019

Enddatum 30 April 2027

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 16 009 225,82

EU-Beitrag

€ 5 687 983,75

Koordiniert durch

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Documents, reports (6)

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular NTM strains in human cells

Zebrafish in vivo test report

The Zebrafish in vivo test report will summarize the methodology and results of the efficacy against known tuberculosis compounds and the effect on granuloma testing in zebrafish larvae for individual NTM compounds

Human NTM in vitro infection Model report

The Human NTM in vitro infection Model report will describe the methodology and assay conditions for an in vitro infection model for NTM (M. avium) in human cells

Purified NTM cytochrome report

The Purified NTM cytochrome report will describe the methodology and confirmation of the biological structures of the purified cytochrome bc1, bc1:aa3, and bd

NTM drug PK report

NTM drug PK report will describe the methodology used and describe the PK model of the NTM drugs

Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report

The Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report will describe the assay, conditions and characterisation methodology of the enzymatic assay for testing cytochrome bc1 and cytochrome bd inhibitors

Websites, patent fillings, videos etc. (1)

Website RESPIRI- NTM online

The website developped for communication of all RespiriNTM activities will be active and online

Veröffentlichungen

Peer reviewed articles (5)

Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria

Autoren: Wanbin Hu, Bjørn E. V. Koch, Gerda E. M. Lamers, Gabriel Forn-Cuní, Herman P. Spaink
Veröffentlicht in: Frontiers in Immunology, 2023, ISSN 1664-3224
Herausgeber: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1075473

Modeling nontuberculous mycobacterial infections in zebrafish

Autoren: Matt D. Johansen Herman P. Spaink Stefan H. Oehlers Laurent Kremer
Veröffentlicht in: Trends in Microbiology, 2023, ISSN 1878-4380
Herausgeber: Cell Press
DOI: 10.1016/j.tim.2023.11.011

Host- directed therapy to combat mycobacterial infections

Autoren: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Veröffentlicht in: Immunological Reviews, Ausgabe 01052896, 2021, Seite(n) 62-83, ISSN 0105-2896
Herausgeber: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium

Autoren: Gül Kilinç, Kimberley V. Walburg, Kees L. M. C. Franken, Merel L. Valkenburg, Alexandra Aubry, Mariëlle C. Haks, Anno Saris1, Tom H. M. Ottenhoff
Veröffentlicht in: Frontiers in Cellular and Infection Microbiology, 2022, ISSN 2235-2988
Herausgeber: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.872361

Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy

Autoren: Gül Kilinç, Ralf Boland, Matthias T. Heemskerk, Herman P. Spaink, Mariëlle C. Haks, Michiel van der Vaart, Tom H. M. Ottenhoff, Annemarie H. Meijer, Anno Saris
Veröffentlicht in: Microbiology Spectrum, Ausgabe 12, 2024, ISSN 2165-0497
Herausgeber: American Society for Microbiology
DOI: 10.1128/spectrum.00167-24